Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors

Inclusion Criteria:

Evidence of metastatic Renal Cell Carcinoma (mRCC) during the study period (May 01, 2016 to March 31, 2020);
Patients who received cabozantinib or non-cabozantinib TKI regimens during identification period (May 01, 2016 to September 30, 2019);
Patients who received CPIs, as monotherapy, or in combination with a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor (e.g. ipilimumab+nivolumab), as the latest treatment for mRCC administrated before cabozantinib or other TKI therapy;
Patients ≥ 18 years of age as of their index date
Patients who received care at a US Oncology Network site
Patients with ≥ 2 visits within the US Oncology Network.

Exclusion Criteria:

Patients enrolled in a clinical trial at any time during index period
Patients receiving treatment for another documented primary cancer diagnoses during the study period